SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : DYAX: Dyax Corp. -- Ignore unavailable to you. Want to Upgrade?


To: DewDiligence_on_SI who wrote (165)3/17/2008 2:41:06 PM
From: idos  Read Replies (1) | Respond to of 197
 
A couple of days ago LEVP announced the FDA's BPAC will review the data for Cinryze on 5/2. Panel review can take 6 more month and so, Cinryze will likely not be approved until Dec.08. CSL Behring are expecting a PDUFA date in early Sep.08 and may be the one capturing orphan exclusivity in acute HAE.
LEVP can still be the only one to be approved for HAE prophylaxis.